2. Academic Validation
  3. Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease

Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease

  • Bioorg Med Chem Lett. 2014 Mar 15;24(6):1472-8. doi: 10.1016/j.bmcl.2014.02.008.
Jie Gao 1,  Bao-Ling Adam 1,  Alvin V Terry Jr 2
Affiliations

Affiliations

  • 1 Department of Pharmacology and Toxicology, CB-3545, Georgia Regents University, 1120 Fifteenth Street, Augusta, GA 30912-2450, United States.
  • 2 Department of Pharmacology and Toxicology, CB-3545, Georgia Regents University, 1120 Fifteenth Street, Augusta, GA 30912-2450, United States. Electronic address: aterry@gru.edu.
PMID: 24581918 DOI: 10.1016/j.bmcl.2014.02.008
Abstract

The currently available therapies for Alzheimer's disease (AD) and related forms of dementia are limited by modest efficacy, adverse side effects, and the fact that they do not prevent the relentless progression of the illness. The purpose of the studies described here was to investigate the neuroprotective effects of the nicotine metabolite cotinine as well as a small series of cotinine and nicotine analogs (including stereoisomers) and to compare their effects to the four clinically prescribed AD therapies.

Keywords

Amyloid; Dementia; Disease modifying; Excitotoxicity; Glutamate; Multi-target-directed ligands; Multifunctional compounds; Neurodegeneration; Neuroprotection; Nicotinic.

Figures
Products